Skip to main content

Table 1 Clinicopathological data according to A-FABP expression

From: Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

 

N(%)

A-FABP

P

Negative

Positive

Population

236 (100)

134 (56.8)

102 (43.2)

–

Sex

 Male

192 (81.4)

111 (82.8)

81 (79.4)

0.503

 Female

44 (18.6)

23 (17.2)

21 (20.6)

 

Age

 Mean (sd)

70.45 (±13.3)

72.1 (±12.8)

68.3 (±13.8)

0.028

Histology

 Papillary

215 (91.1)

118 (88.1)

97 (95.1)

0.06

 Variants*

21 (8.9)

16 (11.9)

5 (4.9)

 

pT

 pTa

114 (48.4)

43 (32.1)

71 (69.6)

< 0.001**

 pT1

61 (25.8)

39 (29.1)

22 (21.6)

 

 pT2

45 (19.1)

40 (29.9)

5 (4.9)

 

 pT3

5 (2.1)

4 (3.0)

1 (1.0)

 

 pT4

11 (4.7)

8 (6.0)

3 (2.9)

 

pN

 0

206 (87.3)

110 (82.1)

96 (94.1)

0.006

 1–2

30 (12.7)

24 (17.9)

6 (5.9)

 

pM

 0

231 (97.9)

130 (97)

101 (99)

0.393

 1

5 (2.1)

4 (3)

1 (1)

 

Grade

 PUNLMP

25 (10.6)

6 (4.5)

19 (18.6)

< 0.001

 LG-UC

76 (32.2)

30 (22.4)

46 (45.1)

 

 HG-UC

135 (57.2)

98 (73.1)

37 (36.3)

 

Cis

 yes

9 (3.8)

7 (5.2)

2 (2)

0.306

 no

227 (96.2)

127 (94.8)

100 (98)

 
  1. *The histological variants include micropapillary, nested, reversed and sarcomatoid variants, urothelial carcinoma with squamous, glandular or neuroendocrine differentiation
  2. **Due to some reduced numbers, the pT3 and pT4 stages were grouped together with the pT2 stage for the Khi-2 test
  3. Abbreviations: PUNLMP Papillary urothelial neoplasm of low malignant potential, LG-UC Low grade urothelial carcinoma, HG-UC High grade urothelial carcinoma, Cis Carcinoma in situ